

BioMarin to Participate in Jefferies Gene Therapy/Editing Summit on October 8, 2019 in New York

SAN RAFAEL, Calif., Oct. 1, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Robert Baffi, Ph.D., President of Global Manufacturing and Technical Operations, will participate in a fireside discussion at the Jefferies Gene Therapy/Editing Summit on October 8, 2019 at 11:15am ET in New York. Dr. Baffi will also participate in the panel discussion on manufacturing, dose, and durability in gene therapy at 10:20am ET, which will not be available by webcast.

To access the live webcast presentation, please visit the investor section of the BioMarin website, www.biomarin.com. A replay will also be archived on the site for at least one week following each event.



About BioMarin

BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare disorders. The company's portfolio consists of seven commercialized products and multiple clinical and pre-clinical product candidates.

For additional information, please visit www.biomarin.com. Information on BioMarin's website is not incorporated by reference into this press release.

Contacts:

Investors

Traci McCarty

BioMarin Pharmaceutical Inc.

(415) 455-7558

Media

Debra Charlesworth

BioMarin Pharmaceutical Inc.

(415) 455-7451

SOURCE BioMarin Pharmaceutical Inc.

<https://investors.biomarin.com/2019-10-01-BioMarin-to-Participate-in-Jefferies-Gene-Therapy-Editing-Summit-on-October-8-2019-in-New-York>